Jana Barinoff

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

Carsten Denkert, Sibylle Loibl, Berit Müller et al. · Annals of Oncology · 2013 · 244 citations · Full text

Breast Oncology, Medicine, Ki67 Levels +8

Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

Gϋnter von Minckwitz, Kathrin Schwedler, Marcus Schmidt et al. · European Journal of Cancer · 2011 · 183 citations

Breast Oncology, Medicine, Pathology +7

Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

Gϋnter von Minckwitz, Wolfgang Schmitt, Sibylle Loibl et al. · Clinical Cancer Research · 2013 · 173 citations · Full text

German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer

Gϋnter von Minckwitz, Volker Möbus, Andreas Schneeweiß et al. · Journal of Clinical Oncology · 2013 · 99 citations